Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Glenmark Pharmaceuticals Inc.
WARNING LETTER
•Glenmark Pharmaceuticals Inc.

Glenmark Pharmaceuticals Inc. – FDA Warning Letter

Record Details

On March 16, 2010, the FDA issued a Warning Letter to Glenmark Generics Inc. regarding their marketing of unapproved new drugs: Nitroglycerin Tablets, 0.3 mg, 0.4 mg, and 0.6 mg.

The FDA determined these products are "new drugs" under section 201(p) of the Act because they are not generally recognized as safe and effective for their labeled uses. Consequently, their introduction into interstate commerce without an FDA-approved application (violating sections 301(d) and 505(a) of the Act) makes them unapproved new drugs.

Additionally, the products are misbranded under section 502(f)(1) of the Act because they are intended for conditions not amenable to self-diagnosis, and their labeling lacks adequate directions for lay use. This also violates sections 301(a) and (d) of the Act.

The FDA stated it would exercise enforcement discretion, not initiating action for manufacturing continuing within 90 days of the letter, or for shipments continuing within 180 days. This discretion would not apply if other violations occur, distribution volume increases, or new serious health risks emerge.

Glenmark Generics Inc. was required to respond within fifteen working days, stating their plan to cease violative activities, including reasons and dates if production ceased, and identifying any other manufacturers or suppliers

Company
Glenmark Pharmaceuticals Inc.
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Deborah M. Autor (Former FDA Deputy Commissioner)
View Company Profile

ID · c8e6ad6f-b7c8-459d-b8f0-e48005ee71ed

Violation Codes10
21 U.S.C. 321(g)(1)(B)21 U.S.C. 321(g)(1)(C)21 U.S.C. 321(p)21 U.S.C. 331(d)21.U.S.C. 355(a)21 U.S.C. 355(b)21 U.S.C. 355(j)21 U.S.C. 352(f)(1)21 CFR 201.11521 U.S.C. 331(a)

Full citation text and observation details available on the Dashboard.

Other documents for Glenmark Pharmaceuticals Inc.
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Glenmark Pharmaceuticals Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.